Nicox signs license agreement with Fera Pharmaceuticals.
M2 EQUITYBITES-November 11, 2015-Nicox signs license agreement with Fera Pharmaceuticals
(C)2015 M2 COMMUNICATIONS http://www.m2.com
Nicox, a France-based pharmaceutical company, has signed a license agreement with Fera Pharmaceuticals.
It was reported yesterday that the contract has been signed to develop and commercialise the company's naproxcinod, a cyclooxygenase-inhibiting nitric oxide-donating anti-inflammatory candidate, in the US.
Fera Pharmaceuticals will initially concentrate on the signs and symptoms of osteoarthritis. Nicox already completed a clinical program for naproxcinod in osteoarthritis, including three phase 3 trials with more than 2,700 patients. The company aims to seek advice from the United States Food and Drug Administration with regard to the further clinical work needed before submitting a new drug application for naproxcinod. The transaction needs Fera to pay around USD35m in sales-based milestones to Nicox. It also includes 7% royalties depending on net sales of naproxcinod in the US.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Nov 11, 2015|
|Previous Article:||Jernigan Capital declares dividend of USD0.35 per share for Q4 2015.|
|Next Article:||Ocata Therapeutics to be acquired by Astellas Pharma.|